(Reuters) – British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create an entity specialised in small molecule-targeted therapeutics and antibody drug discovery to treat cancer and fibrotic disease.
The all-share merger deal will create a new company called Redx Inc and will be listed on Nasdaq, the companies said on Thursday.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Sohini Goswami)
